In adults with MI and LVEF >/=40%, beta-blocker therapy reduced a composite adverse outcome at a median 3.5 y. Leiva O, Elgendy IY. Ann Intern Med 2025;178:JC135.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leiva O, Elgendy IY. In adults with MI and LVEF >/=40%, beta-blocker therapy reduced a composite adverse outcome at a median 3.5 y. Ann Intern Med 2025;178:JC135.
PMID: 41325614